Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER plus breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number1415
JournalCancer research
Volume81
Issue numberSuppl. 13
ISSN0008-5472
DOIs
Publication statusPublished - Jul 2021
EventAACR Annual Meeting 2021 - Philadelphia, United States
Duration: 10. Apr 202115. Apr 2021

Conference

ConferenceAACR Annual Meeting 2021
Country/TerritoryUnited States
CityPhiladelphia
Period10/04/202115/04/2021

Cite this